Efficacy of transcatheter arterial chemoembolization combined with antiviral therapy on hepatocellular carcinoma and its effect on Child-Pugh score and survival rate

Objective To investigate the effect of transcatheter arterial chemoembolization combined with antiviral therapy on hepatocellular carcinoma and its effect on Child-Pugh score and survival rate of patients with hepatocellular carcinoma. Methods Seventy-two cases of hepatocellular carcinoma were selected from January 2014 to May 2015. According to the different treatment options, they were divided into study group and control group, with 36 cases in each group.The control group was only treated with transcatheter arterial chemoembolization, and the study group was treated with anti viral therapy on the basis of hepatic artery chemoembolization.The clinical efficacy and different follow-up times (the third, 6, 12 months) survival rates, and the Child-Pugh score changes before and after treatment were compared. Results The stability of the study group (86.11%) and the effective rate (44.44%) compared with the control group (83.33%, 38.88%), the differences were not significant (P>0.05); Before treatment and after treatment for 3 months of two groups of Child-Pugh score comparison, the difference was not significant (P>0.05), 6 and 12 months of treatment, the Child -Pugh scores were significantly better than those of the control group, the difference were significant (P 0.05). The survival rate (44.44%) in the study group was significantly higher than that in the control group (22.22%) at the twelfth months, and the difference was significant (P<0.05). Conclusions In the transcatheter arterial chemoembolization therapy in patients with hepatocellular carcinoma (HCC) implementation of the antiviral treatment effect is remarkable, can effectively inhibit hepatitis B virus replication, improve the liver function of patients and improve the long-term survival rate and has the value of popularization. Key words: Transcatheter arterial chemoembolization; Antiviral therapy; Hepatocellular carcinoma; Child-Pugh score